Indivior Plc (LON:INDV) Rating Reaffirmed
They currently have a GBX 240.00 target on Indivior Plc (LON:INDV). The target price by Deutsche Bank would suggest a potential upside of 22.45% from the company’s last stock close. This has been disclosed to clients in a recent research report on Monday morning.
From a total of 5 analysts covering Indivior Plc (LON:INDV) stock, 4 rate it a ”Buy”, 0 a “Sell”, and 1 a ”Hold”. This means that 80% of the ratings are positive. The highest target price is GBX 310 while the lowest target price is GBX 240. The mean of all analyst targets is GBX 269 with a 40.47% above today’s (GBX 191.5) stock price. Indivior Plc was the topic of 18 analyst reports since July 29, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank maintained shares on November 30 with “Buy” rating. Citigroup upgraded shares to “Buy” rating and GBX 270 target share price in a report from a September 22. Jefferies maintained INDV stock in a recent report from November 25 with “Buy” rating. Finally, Morgan Stanley maintained the stock with “Equal-Weight” rating in a report issued on a July 24.
The stock closed the day at GBX 191.5 during the previous session. It is down 5.71% since May 1, 2015 and is downtrending. It has underperformed by 4.82% the S&P500.
Indivior PLC is a specialty pharmaceutical company. The company has a market cap of 1.38 billion GBP. The Firm and its subsidiaries are engaged in the development, manufacture, and sale of buprenorphine prescription drugs for the treatment of opioid dependence. It has 7.73 P/E ratio. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine overdose and the co-morbidity of schizophrenia.